Glycemicon
Swiss Biotechnology Company
Glycemicon AG is a Swiss biotechnology company developing novel nutraceutical for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels.
GLYCEMICON STANDS FOR "GLYCEMIC CONTROL"
Learn more
THBA - Our lead substance
Glycemicon’s lead substance, THBA, is a type of bile acid that is naturally occurring. It modifies body fat tissue, making it more efficient in decreasing elevated blood sugar levels – a key feature for the management of prediabetes and diabetes.
Learn more
Natural product for managing prediabetes, diabetes and obesity
We combine strong expertise in adipose tissue biology, diabetes and obesity with the top-notch synthetic chemistry of natural product and small molecules. Close interactions with academic collaboration partners, such as the ETH in Zurich, Switzerland, will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of prediabetes, type 2 diabetes and obesity.
Learn moreNews
Glycemicon Receives CTI Start-up Label
Four new CTI Start-up Label companies were selecte...
View More